MYGN:NASDAQMyriad Genetics, Inc. analysis
Data as of Oct 11, 2026 - not real-time
- Latest price
- $4.31
- Risk: high
- 9/10High risk
Summary
At $4.31, Myriad Genetics, Inc. shows no decisive moving-average alignment, leaving the trend neutral. It has gained 35.5% over the past 30 days. Relative strength is 58.3 — neutral — and the MACD signal is bullish. The recent range runs from support at $3.42 up to resistance at $4.83.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 6.0% below the current quote. Revenue is contracting at 10.5% on a -14.0% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 62.7%, a beta of 1.10 and a maximum drawdown of 65.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 6.0% below the current quote. Revenue is contracting at 10.5% on a -14.0% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 62.7%, a beta of 1.10 and a maximum drawdown of 65.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
Top market events
- Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad...
- Shares of genetic testing company Myriad Genetics NASDAQ:MYGN fell 6.
- Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Trading below the 200-day average of 4.69
- MACD momentum is positive
- 30-day price change of +35.5%
Medium term
1–3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- Trading below the 200-day average of 4.69
- Analyst targets imply -6.0% versus the current price
- 30-day volatility of 62.7%
Long term
> 3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Negative profit margin of -14.0%
- Analyst targets imply -6.0% versus the current price
- Negative return on equity of -32.5%
Key metrics
Financial health
Revenue Growth-10.50%
Profit Margin-13.96%
P/E Ratio-7.3
ROE-32.54%
ROA-8.60%
Debt/Equity69.27
P/B Ratio1.4
Op. Cash Flow$7.7M
Free Cash Flow$18.2M
Industry P/E30.5
Technical analysis
TrendNeutral
RSI58.3
Support$3.42
Resistance$4.83
MA 20$4.15
MA 50$3.56
MA 200$4.69
MACDBullish
VolumeDecreasing
Fear & Greed Index94.93
Valuation
Fair Value$1.27
Target Price$4.05
Upside/Downside-6.03%
GradeOvervalued
TypeBlend
Risk assessment
Beta1.10
Volatility62.67%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.